

Appendix 3X

Initial Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX becomes ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	Tryptamine Therapeutics Limited
ABN	78 163 765 991

We (the entity) give ASX the following information under listing rule 3.19.A.1 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of director	Daniel Tillett
Date of appointment	08 November 2024

Part 1 - Director's relevant interests in securities of which the director is the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Number & class of securities
12,000,000 - ORDINARY FULLY PAID SHARES

Part 2 - Director's relevant interests in securities of which the director is not the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Name of holder & nature of interest <i>Note: Provide details of the circumstances giving rise to the relevant interest.</i>	Number & class of Securities
N/A	N/A

Part 3 - Director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	Subscriber, subject to shareholder approval, in the two tranche capital raising.
Nature of interest	Subscriber, subject to shareholder approval, in the two tranche capital raising as announced by TYP on 30 October 2024. The EGM and Placement, subject to shareholder approval, are expected to occur in January 2025.

Appendix 3X

Initial Director's Interest Notice

Name of registered holder (if issued securities)	Daniel Tillett
No. and class of securities to which interest relates	50,000,000 - ORDINARY FULLY PAID SHARES 25,000,000 - UNLISTED OPTIONS EXERCISABLE AT \$0.04 AND EXPIRING 2 YEARS FROM THE DATE OF ISSUE

+ See chapter 19 for defined terms.